AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$MIRM

BJERKHOLT ERIC sold $978K of MIRM

BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) sold 9,943 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $98.37 ($0.98M total) on 2026-09-14.

Original reporting
SEC EDGAR · BJERKHOLT ERIC
Published Sep 15, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MIRM
Bearish
medium confidence
Mentioned
$MIRM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MIRMBearishLow
01

Why it matters

The CFO's sale reduces insider ownership, which can be interpreted as a negative signal, but the size is relatively small.

02

Market read

A modest insider sale that may cause slight short‑term price pressure.

03

What to watch

The CFO may have needed liquidity for personal reasons; no direct link to company performance.

Relevance 5/10Novelty 4/10Timing: post-filing today

Background

Form 4 filings disclose insider transactions and are considered primary sources of new information.

Company-level read

Ticker impact

$MIRMBearishMedium confidence
Context

CFO Eric Bjerkholt sold 9,943 shares for $978,092, reducing his stake to 44,745 shares.

Expected impact

Potential modest dip of 1‑2% in the near term.

Evidence & confidence

A $978k sale by a senior officer is material for a micro‑cap biotech, but the amount is modest relative to market cap.

Market effects

Sector

May raise concerns among investors in the biotech sector about insider sentiment.

Regional

Limited to U.S. markets where MIRM trades.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing unrelated to company fundamentals.

Key entities

  • Company
    Mirum Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ under ticker MIRM.

  • Executive
    Eric Bjerkholt

    Chief Financial Officer of Mirum Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MIRM insider trading history →

Related articles

NOV 2
$MIRMHighAI 8/10

Mirum will present longer-term hepatitis D response data, including in people with cirrhosis.

Mirum Pharmaceuticals will present data on its hepatitis D treatment, brelovitug, at The Liver Meeting 2026, including Phase 3 results and longer-term efficacy in patients with cirrhosis. The company will also share additional analyses on volixibat for primary sclerosing cholangitis (PSC) and new evidence on LIVMARLI (maralixibat) for rare cholestatic liver diseases.

stocktitan.net3 min
OCT 26
$MIRMMedAI 8/10

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals (MIRM) reported positive results from Cohort 2 of the PROGRESS study for ATEBRIOZ (zilurgisertib) in pediatric FOP patients aged 6 to <12. The drug reduced HO lesion volume and improved joint mobility, with no new lesions. Mirum plans an sNDA submission in H1 2027 to expand the indication. Safety findings were consistent with prior data.

financialcontent.com2 min
OCT 26
$MIRMHighAI 9/10

Mirum Pharmaceuticals Reports Positive Pediatric ATEBRIOZ Study Results

Mirum Pharmaceuticals reported positive results from a pediatric study of ATEBRIOZ, showing reduced heterotopic ossification and improved joint mobility in children aged 6 to under 12 with FOP. At Week 24, lesion volume decreased by 8.09 cm³ with zilurgisertib and increased by 9.14 cm³ with placebo. The company plans to submit an sNDA in the first half of 2027 for expanded use.

tradingview.com1 min
OCT 26
$MIRMMedAI 9/10

Mirum Pharmaceuticals, Inc. (MIRM): Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with…

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva On October 26, 2026, Mirum Pharmaceuticals, Inc. (the “Company”)

SEC EDGAR 8-K2 min